Vericel (VCEL) Current Deferred Revenue (2015 - 2018)
Vericel's (VCEL) quarterly Current Deferred Revenue came in at $566000.0 in Q4 2018, up 34.76% year-over-year from $420000.0 in Q4 2017, and up 5.99% quarter-over-quarter from $534000.0 in Q3 2018.
Analysis
Vericel (VCEL) Current Deferred Revenue (2015 - 2018) Analysis & Trends
Vericel has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $566000.0 for Q4 2018.
- In Q4 2018, Current Deferred Revenue rose 34.76% year-over-year to $566000.0; the TTM figure through Dec 2018 stood at $566000.0 (up 34.76% YoY), while the FY2018 annual figure was $566000.0, up 34.76% from the prior year.
- Current Deferred Revenue came in at $566000.0 for Q4 2018 at Vericel, up from $534000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $566000.0 in Q4 2018 to a low of $3000.0 in Q4 2016.
- Average Current Deferred Revenue over 4 years is $362444.4, with a median of $426000.0 recorded in 2018.
- Year-over-year, Current Deferred Revenue sank 97.46% in 2016 and jumped 13900.0% in 2017.
- Over 4 years, Current Deferred Revenue stood at $118000.0 in 2015, then slumped by 97.46% to $3000.0 in 2016, then jumped by 13900.0% to $420000.0 in 2017, then soared by 34.76% to $566000.0 in 2018.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $566000.0 in Q4 2018, $534000.0 in Q3 2018, and $503000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.26 Bn | 9.41 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.19 Bn | 5.19 Bn | - |
| 3 | Iovance Biotherapeutics | 3.76 Bn | 3.46 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.67 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.54 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 566,000.00 |
| Sep 30, 2018 | 534,000.00 |
| Jun 30, 2018 | 503,000.00 |
| Mar 31, 2018 | 426,000.00 |
| Dec 31, 2017 | 420,000.00 |
| Dec 31, 2016 | 3,000.00 |
| Sep 30, 2016 | 232,000.00 |
| Jun 30, 2016 | 460,000.00 |
| Dec 31, 2015 | 118,000.00 |